Surprisingly, our drug virtual screening against four databases (Selleck, DiscoveryProbeFDA-approved Drug Library, DrugBank and Binding Database) identified that bleomycin sulfate(Blexane, Blenoxane), a mixture of cytotoxic glycopeptide antibiotics approved for squamouscell carcinoma, lymphoma, testicular carcinoma and malignant pleural effusion, exhibitedreasonably strong binding to both FN1 and Serpin B5 (Figure4 and Supplementary TableS1 and Figure S1). Here, FN1 is linked to lymphoma.